title: Hospital policies for treatment of acute decompensated heart failure.
abstract: BACKGROUND
  It is unclear to what extent hospitals use guidelines or protocols in treating acute decompensated heart failure (ADHF) and whether nesiritide is included in these guidelines or protocols.
  
  
  OBJECTIVE
  To assess the formulary status of currently used drugs, therapeutic guidelines, and perceptions about the appropriateness of treatment of ADHF in community hospitals.
  
  
  METHODS
  A Web-based survey of pharmacy directors at community hospitals that were part of a national group purchasing organization was conducted.
  
  
  RESULTS
  One hundred seven hospitals participated in the survey (response rate 47.1%). Diuretics such as furosemide and bumetanide were more commonly included (100% and 94.4%, respectively) on hospital formularies than was torsemide (69.2%). Dopamine and dobutamine were more common (94.4% each) on the formulary than was milrinone (68.2%). Nitroprusside and nitroglycerin were listed on the formularies of more than 90% of participating institutions, while nesiritide was listed on the formularies in only 48.6% of hospitals and was placed on restricted status in 36.4% of hospitals. Guidelines for care of patients with ADHF were used in the emergency department (ED), inpatient care units, and outpatient clinics in 18.6%, 43.0%, and 8.5% of hospitals, respectively. Overall, ADHF care, including general treatment as well as specific use of nesiritide, was deemed appropriate in the majority of patients, but nearly twice as many respondents perceived the management of ADHF and specific use of nesiritide as inappropriate in the ED compared with inpatient treatment. Only 41.1% of the respondents reported following Braunwald recommendations for the use of nesiritide.
  
  
  CONCLUSIONS
  A sizable percentage of responding community hospitals do not have guidelines for treatment of ADHF despite the existence of such guidelines in the literature. There are opportunities for improvement in the general treatment of ADHF as well as for the use of nesiritide in ADHF, especially in the ED or observation unit versus inpatient units.
authors: Center for Pharmacoeconomic Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
authors: Vikrant
authors: V
authors: Vats
authors: Robert J
authors: RJ
authors: DiDomenico
authors: Jeffrey E
authors: JE
authors: Wojtynek
authors: John C
authors: JC
authors: Theobald
authors: Glen T
authors: GT
authors: Schumock
mesh_terms: D004232:Diuretics / Q000627:therapeutic use*; D006291:Health Policy; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology; D006764:Hospitals, Community / Q000706:statistics & numerical data*; D006801:Humans; D020097:Natriuretic Peptide, Brain / Q000627:therapeutic use; D045265:Natriuretic Peptides / Q000627:therapeutic use; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data*; D017410:Practice Guidelines as Topic; D011795:Surveys and Questionnaires; D014481:United States / Q000453:epidemiology; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D004232:Diuretics; D045265:Natriuretic Peptides; D014665:Vasodilator Agents; D020097:Natriuretic Peptide, Brain